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different extents, it becomes especially important to make 
corrections for tissue attenuation when the relative amounts 
of lung and oropharyngeal deposition are expected to be 
different for the two products, and it will not be satisfactory 
to make no correction on the basis that subjects act as their 
own controls. In addition, failure to correct for tissue 
attenuation will produce data that cannot be compared 
directly with those obtained elsewhere for other products. 
Based upon the above considerations, it is probable that 
the 13-fold difference in lung deposition values between 
CFC and HFA products reported by Leach (3) is caused in 
part by inaccurate quantification of the data, especially for 
the CFC product. Earlier this year, a workshop was held in 
London under the auspices of the British Association for 
Lung Research, which set out guidelines to ensure the 
correct conduct of scintigraphic studies in terms of their 
design and technical aspects, and to allow data obtained in 
different scintigraphic centres to be compared more readily. 
Amongst these guidelines was the need to generate and 
display adequate radiolabelling validation data for all 
products tested, and the need to make corrections for the 
effects of tissue attenuation of gamma rays. The workshop 
report has been published in Respiratory Medicine (13). 
There are plans to revisit these issues at another workshop 
to be held as part of the international Society for Aerosols 
in Medicine bi-annual congress in Vienna in June 1999. 
The clinical response to inhaled corticosteroids is very 
difficult to measure: since these drugs act over relatively 
long time periods, and have flat dose response curves. The 
quantification of lung deposition data for inhaled asthma 
drugs can serve as a valuable surrogate for clinical 
response, but only providing that the technical issues 
associated with quantification of the deposition data have 
been addressed appropriately. 
S. P. NEWMAN, MD AND G. R. PITCAIRN, MD 
Pharmaceutical Pvojles, Highfields Science Park, 
University Botaleuavd, Nottingham, NGi’ ,?.QP, U.K. 
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Reply to Drs Newman and Pitcairn 
We have read the ‘Letter to the Editor’ tendered by 
Drs Newman and Pitcairn regarding our paper in 
Respbatory Medicine (1), and we offer the following 
response. Dr Newman refers to the fact that detailed 
technical support of some of the data presented was not 
provided in the manuscript. The articles published in the 
supplement represent verbal overviews of many clinical 
studies presented in a symposium at the 1997 European 
Respiratory Society Meeting in Berlin. As such, the detailed 
experimental methods of all of the studies cited would have 
required several volumes of Respiratory Medicine to 
present. Obviously this is well beyond the scope or intention 
of the Supplement. Dr Newman has therefore chosen to go 
back to abstracts that represent a small portion of the work 
presented and criticize the techniques. Complete details of 
two of the studies cited in the symposium are presented in a 
recent article published in the European Respiratory Journal 
(2) and many of the issues raised are addressed there. 
However, the authors would like to address the specific 
questions raised here. 
The authors agree that the essential element of any 
radiolabelled deposition study is the validation of the 
association of the radiolabel with the drug. Toward 
that end, the authors developed the Andersen Impactor 
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validation method described in the European Respiratory 
Journal paper cited above (2). The Andersen validation 
method is now becoming the standard technique for radio- 
labelled deposition studies. In this method, association of 
the radiolabel is plotted against the mass distribution for all 
stages of the Andersen Impactor, including the MD1 
actuator, the throat, stage 0, and the final filter. Because the 
BDP in HFA-BDP (QVAR@, 3M Pharmaceuticals) is 
dissolved in the formulation in the can, it was expected and 
proven that the radiolabel (i.e. technetium-99m) was in 
infinite contact with the drug molecules and therefore as the 
drug particle is formed during the aerosolization process, 
the technetium is automatically incorporated into the final 
drug aerosol particle. Indeed the validation showed that 
this was the case. Thus the radiolabel association with BDP 
from QVAR probably represents the best case of all 
radiolabel-drug associations. This is different from CFC- 
BDP pMDIs because these products contain pre-formed 
particles suspended in the liquid CFC propellant inside the 
pMD1 cans. In the suspension product, the radiolabel must 
associate with the surface or surface craters of the existing 
drug particles. Because of surface area to volume relation- 
ships, the larger particles are more subject to this potential 
error than small particles in that proportionately more 
molecules in the center of large particles are hidden from 
the radiolabel. Thus it was expected and indeed shown that 
the degree of association of radiolabel with CFC products 
is not as complete as it is with QVAR. This situation is not 
new and it is undoubtedly the case with all previous 
radiolabelled drug deposition work on suspension pMD1 
products reported throughout the literature. The question 
is, how good must the association be to give a reasonable 
representation of the remaining unlabelled drug? There are 
no standard or even common ways to answer this question. 
Dr Newman refers to an F-2 statistical method adapted 
from oral studies but there is no such analysis presented in 
his deposition papers (3-10). Because of the lack of stand- 
ardization, we have always chosen to use the most discrimi- 
nating methods available, publish those details along with 
the results, and let the reader decide if the label is good 
enough to give an accurate representation of drug delivery. 
Obviously, the authors considered the association of 
radiolabel with the CFC-BDP to be acceptable, but we are 
careful to disclose this potential error. Additional valida- 
tion procedures used in our laboratory include a prestudy 
radiolabelling validation as well as actual study day valida- 
tion on every single pMD1 used by a patient. This valida- 
tion scheme is well beyond what has been described 
in previous radiolabelled deposition studies (3-10). Dr 
Newman has published extensively in the area of radio- 
labelled deposition and those studies include a validation 
technique using the four-stage liquid impinger whereby the 
first stage is a cut-off for particles > lOpurn (3-10). Thus, 
the liquid impinger possesses only three stages of actual 
resolution. This compares with seven stages of resolution 
for the Andersen Impactor used in the QVAR deposition 
studies. We have found that using the liquid impinger can 
at times lead one to believe the radiolabel is well associated 
with drug while the Andersen with its greater resolution can 
easily show that the radiolabel is not associated with 
drug. In addition, the validation methods published by 
Dr Newman include only pre-study validation runs and not 
validation on every pMD1 used by a patient (3310). 
Dr Newman finds that lung deposition numbers for 
QVAR as high as 51% to be a ‘remarkable result’ presum- 
ably based on historical values of CFC-BDP and indeed all 
other pMDIs being considerably lower (3). Greater lung 
deposition was intentionally designed into the product from 
the outset. QVAR is the only pMD1 to deliver the optimal 
particle size of 1.1 pm necessary for efficient lung deposi- 
tion. Fortunately, the forced removal of CFCs from all 
products has allowed companies the opportunity to com- 
pletely redesign pMDIs from the ground up. It is well 
known that CFC inhalers deposit most of the drug in the 
mouth. Hence the widespread use of spacer devices. Some 
new generations of pMDIs will exhibit much greater effi- 
ciency because of the greater understanding of aerosol 
medicine, the site of disease within the lungs, and new 
analytical development tools. There are pMDIs in 
development which can deliver ~90% lung deposition. 
Dr Newman has also stated that ‘no other pMDIs are as 
low as 4%’ lung deposition. The values cited in our paper 
are 3-8% lung deposition for CFC-BDP. This range is 
derived from several independent studies performed in our 
laboratory. To the best of our knowledge, there are no 
formal publications where CFC-BDP lung deposition has 
been measured in humans. The single reference to CFC- 
BDP lung deposition (outside of our laboratory) appeared 
in abstracts authored by Warren et al. at the 1997 AAPS 
meeting (11) and again at the 1998 RDD-VI meeting (12). 
They reported lung deposition values of 8.7 + 5.3%. These 
values are ex-valve numbers and have been multiplied by 
tissue attenuation factors. These study results are in good 
agreement with the numbers we have reported. Addition- 
ally, there are other reports of pMD1 lung deposition values 
in that range. Dr Newman has reported lung deposition of 
DSCG pMD1 to be 8.8% (10). Dr Newman has also 
reported 11.0 * 4.9% lung deposition for fenoterol pMD1 
(5) and 10.7 f 2.6% for terbutalene pMD1 (8). Dr Newman 
has expressed these data as ex-valve amounts multiplied by 
unspecified attenuation factors. Thus the values reported by 
our laboratory of 338% for CFC-BDP (ex-adapter amounts 
but not multiplied by attenuation factors) do not appear to 
be extraordinary. 
Drs Newman and Pitcairn have commented that the 
deposition data we present have not been multiplied by 
tissue attenuation factors. However, there are no actual 
attenuation numbers present in their manuscripts (3-10) 
thus making independent assessments impossible. There is 
probably no issue other than validation that is more 
controversial in deposition studies than that of tissue 
attenuation multiplication. There is no doubt that various 
tissues absorb and scatter some of the gamma emissions 
from the radiolabel. A full review of attenuation correction 
advantages and disadvantages is well beyond the scope of 
this letter. Perhaps the simplest, most intuitive reason why 
current tissue attenuation factors are not accurate is the fact 
that the methods attempt to predict attenuation based on 
even distribution of radiolabel within the lung. Obviously a 
drug which deposits primarily in the central part of the 
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lungs will have a difference attenuation from a drug which 
deposits in the periphery, which in turn will have a different 
attenuation from a drug which deposits evenly throughout 
the lungs. Current attenuation techniques would assign the 
same multiplication factor for a given person regardless of 
the site of deposition of the drug within the lungs. This 
represents an inherent error in the attenuation estimation. 
Cross et al. (13) have pointed out that alternative attenua- 
tion methods such as macroaggregated albumin (MAA) 
scanning rely on the assumption that the intrapulmonary 
distribution of the injected MAA activity and the aerosol 
drug are similar. We have performed attenuation estima- 
tion techniques as part of our studies but we have chosen 
not to use these multiplication factors because we do not 
believe they have been validated. Rather than apply ques- 
tionable multiplication factors, the authors have always 
chosen to present raw numbers and clearly state that no 
multipliers were used. Interestingly, the use of multiplica- 
tion factors typically reported in the literature (14) actually 
makes QVAR appear to have even more lung deposition 
than the unmanipulated values we report. Finally, the need 
to perform such attenuation multiplications was reduced or 
eliminated since the same patients using identical inhaler 
technique inhaled both the QVAR and the CFC-BDP in a 
cross-over design. Perhaps some of the most convincing 
supportive data come from the extensive clinical efficacy 
and pharmacokinetic program conducted on QVAR. 
Patients inhaling both the QVAR and CFC-BDP exhibited 
the relative pharmacokinetic profile predicted by the 
deposition studies (2,15). 
CHET LEACH, PHD 
3M Pharmaceuticals, 3M Center, Building 270-35-05, 
St Paul, MN 55144-1000, U.S.A. 
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